noradrenaline reuptake inhibitor

(redirected from Norepinephrine reuptake inhibitor)
Also found in: Acronyms, Wikipedia.

noradrenaline reuptake inhibitor

One of a class of drugs that function by increasing the available amount of the neurotransmitter NORADRENALINE at synapses. This is achieved by interfering with the normal physiological reuptake mechanism that brings about the removal of noradrenaline from the synaptic gap. Selective noradrenaline reuptake inhibitors can have a useful antidepressive effect. They include AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, AMOXAPINE, MAPROTILINE and NORTRIPTYLINE.
References in periodicals archive ?
The US Food and Drug Administration (FDA) has accepted United States-based Sunovion Pharmaceuticals' New Drug Application for Dasotraline, a novel dopamine and norepinephrine reuptake inhibitor intended for the treatment of patients with moderate-to-severe binge eating disorder (BED), it was reported yesterday.
It is the first dopamine and norepinephrine reuptake inhibitor approved to treat those conditions.
According to the company, Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved to treat excessive daytime sleepiness in adults living with narcolepsy or OSA.
It has new chapters on deprescribing and managing substance use disorders in adolescents; more coverage of injectable medications; discussion of weight stabilization medications; new tables; an updated chapter on sympathomimetic amines, central nervous system stimulants, and executive function agents to include new medications that enhance attentional function; updated chapters on antiepileptic mood stabilizers and lithium carbonate and non-SSRI (selective serotonin reuptake inhibitor)/SNRI (serotonin and norepinephrine reuptake inhibitor) anxiety medications; and an updated chapter on second and third-generation antipsychotic/mood stabilizer medications to include third-generation antipsychotics and greater emphasis on clinical treatment.
PARIS--Of patients with major depressive disorder who receive a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) as their initial pharmacotherapy, 40% do not achieve the minimum therapeutic dose within 4 weeks of diagnosis, according to a real-world study of U.S.
If SSRIs aren't effective, a serotonin and norepinephrine reuptake inhibitor (SNRI) may be prescribed.
receptor, but also a serotonin and/or norepinephrine reuptake inhibitor (SNRI).
One group received escitalopram (a selective serotonin reuptake inhibitor, or SSRI) and a placebo; the second group received the same SSRI paired with bupropion (a nontricyclic antidepressant); and a third group took different antidepressants: venlafaxine (a tetracyclic antidepressant) and mirtazapine (a serotonin norepinephrine reuptake inhibitor).
For managing vasomotor symptoms such as hot flashes, the guideline recommends that - because hormonal therapy is generally contraindicated in women with hormone-positive breast cancer - an SSRI, an SNRI (serotonin norepinephrine reuptake inhibitor), or gabapentin be used instead.
A third group took different antidepressants: venlafaxine (Effexor[R], a tetracyclic drug) and mirtazapine (Remeron[R], a serotonin norepinephrine reuptake inhibitor, or SNRI).
Atomoxetine, a norepinephrine reuptake inhibitor, was approved in 2002 as the first nonstimulant medication for attention-deficit/hyperactivity disorder (ADHD).
Reboxetine is a selective norepinephrine reuptake inhibitor used in the United Kingdom.